Immunotherapy of Melanoma: A New Era

摘要: After decades of phase III trials failing to demonstrate an impact on survival by cytokine-based regimens and the lack progress in development therapeutic vaccines patients with metastatic melanoma, novel ways modulating immune system monoclonal antibodies have changed landscape. For first time a clinically important statistically significant systemic therapy advanced melanoma has been developed. Immunotherapy finally established itself is here stay. The ipilimumab-based immunotherapy new corner stone for many subsequent developments. Other are being developed substantial hope emerging that these developments may be able provide future so far stagnant effective disease.